CPE points: 4.5

For more information:

/ufiles/userfiles/files/HKSDO%20ASM%202026_poster_20260724(1).pdf

Learning Objectives of the Symposium By the end of this symposium, participants will be able to:

1. Implement Holistic Management of CLDN18.2-Positive Gastric/GEJ Cancer: Evaluate precision patient selection, proactive safety optimization, and emerging therapeutic horizons in managing CLDN18.2-positive gastric and gastroesophageal junction cancers.

2. Analyze Innovations in HER2-Positive Gastric Cancer: Assess the impact of zanidatamab and tislelizumab in the treatment of HER2-positive advanced gastric cancer, based on findings from recent clinical trials.

3. Examine Evolving Roles of Immunotherapy in Unresectable HCC: Evaluate the emerging evidence supporting immunotherapy combinations in unresectable hepatocellular carcinoma (HCC) and their implications for treatment algorithms.

4. Understand Latest Guideline Updates in mCRC: Review the 2026 ESMO guidelines for metastatic colorectal cancer, focusing on the integration of biomarker-driven strategies and treatment planning.

5. Assess Breakthroughs in Early-Stage dMMR/MSI-H Colorectal Cancer: Analyze the clinical rationale and safety data from recent trials to understand advancements in the management of early-stage dMMR/MSI-H colorectal cancer.

6. Integrate Multidisciplinary Insights: Synthesize knowledge from the symposium sessions to enhance clinical decision-making, optimize patient outcomes, and leverage innovative, evidence-based therapeutic strategies across diverse cancer types.